Basic information Biological Activity Safety Related Supplier

ChemicalBook Product Catalog Atezolizumab

1/1

Atezolizumab NEW

$228.00 1mg

$543.00 5mg

$788.00 10mg

Min. Order
Purity95.20%
Cas No1380723-44-3
Supply Ability10g
Update time2026-04-14

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Atezolizumab
CAS No	1380723-44-3
EC-No
Min. Order
Purity	95.20%
Supply Ability	10g
Release date	2026/04/14

Product Introduction

Bioactivity

Name	Atezolizumab
Description	Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
Cell Research	Objective: Determine the binding of [111In]PD-L1-mAb to tumor cell lines. Cells: NCI-H2444（Lung Cancer cell line）, MDAMB231（Breast Cancer cell line）,etc. Concentrations: 1 μCi/100μl. Incubation Time: 1 h. Method: Incubating 1 μCi of [111In]PD-L1-mAb with 1×106cells (in triplicate for each cell line) for 1h at 37°C. PD-L1 blocking was performed by adding a 10-fold molar equivalent excess of the non-labeled mAb. After incubation, cells were washed three times with cold PBS prior to counting on an automated gamma counter.
In vitro	METHODS: MDA-MB-231, BT-20, MDA-MB-468 cells and T cells were co-cultured and treated with Atezolizumab (50-100 µg/mL) for 4-24 h. T cell-mediated cytotoxicity assay was performed. RESULTS: Atezolizumab significantly enhanced T cell-mediated cytotoxicity of MDA-MB-231 cells in a dose-dependent manner, with 100 µg/mL concentration of Atezolizumab showing significant efficacy at 4 and 24 h incubation.Similar results were obtained with BT-20. No Atezolizumab-induced T cell-mediated cytotoxicity was observed in PD-L1- MDA-MB-468 cells compared to MDA-MB-231 and BT-20 cells. [1] METHODS: MDA-MB-231 cells were treated with Atezolizumab (0.5 µg/mL) for 24 h. Surface expression of PD-L1 was detected by flow cytometry. RESULTS: Almost all MDA-MB-231 cells were positive for PD-L1, but the detection of PD-L1 epitopes was blocked by the specific antibody Atezolizumab after 24 h treatment. [2]
In vivo	METHODS: To detect in vivo antitumor activity, Atezolizumab (10 mg/kg) and Bevacizumab (5 mg/kg) were intraperitoneally injected into BALB/C nude mice bearing A2780cis xenografts every two days for three weeks. RESULTS: In vivo treatment with Atezolizumab or Bevacizumab induced significant antitumor effects and significantly inhibited tumor growth. Dual blockade with Atezolizumab and Bevacizumab significantly inhibited tumor growth compared to each treatment. [3]
Storage	Shipping with blue ice/Shipping at ambient temperature.
Keywords	PD-L1 \| PDL1 \| PD-1/PD-L1 \| PD1/PDL1 \| PD-1 \| PD1 \| MPDL3280A \| Inhibitor \| inhibit \| Autophagy \| Atezolizumab \| Apoptosis
Inhibitors Related	Stavudine \| Aceglutamide \| Hemin \| Urea \| Tamoxifen \| Guanidine hydrochloride \| Hydroxychloroquine \| Metronidazole \| Formamide \| Paeonol \| Naringin \| Alginic acid

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy